TRuE-AD4 enrolled adults with 10%–20% BSA moderate atopic dermatitis and prior inadequate response, intolerance, or contraindication to standard topical therapies, continuing as-needed ruxolitinib ...

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids ...

Week-24 TRuE-AD4 outcomes with ruxolitinib 1.5% cream showed 84.3% EASI75 and 70.6% IGA Treatment Success among completers continuing PRN after Week-8 response. Enrolled adults had moderate AD ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura ® (ruxolitinib) cream in ...

Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura ® (ruxolitinib) cream in adults with moderate atopic dermatitis ...

Need tabloid-size output in the office, or truly big photo prints at home? These top-rated wide-format printers handily produce documents and photos on paper that's 11 by 17 inches or larger—in some ...

Forbes contributors publish independent expert analyses and insights. Rachel Wells is a writer who covers leadership, AI, and upskilling. This voice experience is generated by AI. Learn more. This ...

Application Letter Writing: Through this article, students can learn about the format of application letter writing. Also, find attached examples for the same. Some important tips for application ...

Deciding which format to use will be determined by the type of script you are writing. Formats are dictated by technology, and there are good reasons for using them. A correctly formatted script makes ...

Incyte has announced promising new data from its phase 3b TRuE-AD4 trial of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD), revealing significant improvements in clinical ...

Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura ® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as ...

The double-blind, randomised, vehicle-controlled study enrolled 241 patients. Credit: TY Lim / Shutterstock.com. Incyte has announced results from the Phase IIIb TRuE-AD4 trial of Opzelura ...